Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma

2003 ◽  
Vol 121 (2) ◽  
pp. 259-269 ◽  
Author(s):  
Thierry Vincent ◽  
Laurence Molina ◽  
Lucile Espert ◽  
Nadir Mechti
Blood ◽  
1986 ◽  
Vol 67 (5) ◽  
pp. 1418-1426 ◽  
Author(s):  
S Tsai ◽  
CA Sieff ◽  
DG Nathan

Abstract A novel cover slip-transfer culture system was designed to study the functional roles of stromal cells in hemopoiesis, particularly erythropoiesis. Human bone marrow stromal cell colonies were allowed to develop on small glass cover slips in liquid medium. The cover slips, along with the stromal cell colonies and progenitors attached to them were then transferred to a new tissue culture dish and overlaid with methylcellulose culture medium. No exogenous colony-stimulating factors except erythropoietin were supplied. Large erythroid bursts, comprising multiple subcolonies, developed on the stromal cells. In order to determine if stromal fibroblasts together with erythropoietin and serum proteins could support erythroid development, human bone marrow cells depleted of monocytes, macrophages, and T lymphocytes were allowed to adhere to monolayers of a homogeneous fibroblastoid human stromal cell strain ST-1 grown on cover slips. The cover slips were then washed to remove nonadherent cells, transferred to a new culture dish, and overlaid with methylcellulose culture medium containing fetal calf serum and erythropoietin. In this modified system as well, primitive erythroid progenitors migrated extensively on and within the stroma to form huge colonies of hemoglobinized erythroblasts that proceeded to enucleate. Our results indicate that (1) ST-1 cells together with serum proteins and erythropoietin can support the development of large erythroid bursts; (2) erythroid progenitors and precursors adhere to and migrate on and within the extracellular matrix elaborated by ST-1 cells; (3) erythroid progenitors are more adherent to the ST-1 cells or the extracellular matrix than are the more mature cells and possibly the myeloid progenitors.


Blood ◽  
2000 ◽  
Vol 96 (2) ◽  
pp. 671-675 ◽  
Author(s):  
Sun Jin Choi ◽  
Jose C. Cruz ◽  
Fiona Craig ◽  
Hoyeon Chung ◽  
Rowena D. Devlin ◽  
...  

Abstract This study was designed to determine if macrophage inhibitory protein-1 (MIP-1), a recently described osteoclast (OCL) stimulatory factor,1 was present in marrow from patients with multiple myeloma (MM) and possibly involved in the bone destructive process. MIP-1, but not interleukin-1β (IL-1β), tumor necrosis factor-β (TNF-β), or interleukin-6 (IL-6), messenger RNA was elevated in freshly isolated bone marrow from 3 of 4 patients with MM compared to normal controls. Furthermore, enzyme-linked immunosorbent assays of freshly isolated bone marrow plasma detected increased concentrations of hMIP-1 (range, 75-7784 pg/mL) in 8 of 13 patients (62%) with active myeloma, in 3 of 18 patients (17%) with stable myeloma (range, 75-190.3), as well as in conditioned media from 4 of 5 lymphoblastoid cell lines (LCLs) derived from patients with MM. Mildly elevated levels of MIP-1 were detected in 3 of 14 patients (21%) with other hematologic diagnoses (range, 80.2-118.3, median value of 96 pg/mL) but not in normal controls (0 of 7). MIP-1 was not detected in the peripheral blood of any patients with MM. In addition, recombinant hMIP-1 induced OCL formation in human bone marrow cultures. Importantly, addition of a neutralizing antibody to MIP-1 to human bone marrow cultures treated with freshly isolated marrow plasma from patients with MM blocked the increased OCL formation induced by these marrow samples but had no effect on control levels of OCL formation. Thus, high levels of MIP-1 are expressed in marrow samples from patients with MM, but not in marrow from patients with other hematologic disorders or controls, and support an important role for MIP-1 as one of the major factors responsible for the increased OCL stimulatory activity in patients with active MM.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 4781-4781
Author(s):  
Tomoiku Takaku ◽  
Daniela Malide ◽  
Ning Zhi ◽  
Rodrigo Calado ◽  
Jichun Chen ◽  
...  

Abstract Three-dimensional (3D) reconstruction of organs and tissues is a powerful tool to establish anatomical and functional relationships of microscopic structures. We developed whole-mount tissue processing methods for 3D in situ visualization of murine and human bone marrow; our methods are compatible with fluorescent labeling of different cell types and other structures of interest in the tissue microenvironment. The major technical problems addressed were the conditions for tissue fixation in the absence of permeabilization and sectioning; antibody penetration and binding; and the acquisition of high quality images by adequate laser scanning confocal microscope. For murine bone marrow, the sternum was bisected sagitally; for human tissue, 2–3 mm fragments of core biopsies were utilized. Bone marrow tissue and cells were exposed to fluorescence labeled nucleic acid dyes and antibodies, with or without prior chemical fixation. Single and double labeling of cells was feasible with combinations of various antibodies and direct and indirect immunofluorescent techniques. In some experiments, cells were visualized from transgenic mice with cell populations expressing green fluorescence protein (GFP). Series of two dimensional (xy) images 600 μm × 600 μm were collected along the z-axis at 5 μm z-intervals to depths of 60–100 μm using a Zeiss LSM 510 confocal microscope. Two dimensional images were assembled to reconstruct 3-dimensional volumes by Bitplane’s Imaris 3D computer software. Antigenicity was preserved, allowing simultaneous labeling of cell types and structures by immunohistochemistry or nuclear dyes. Different hematopoietic cell types as well as blood vessels, adipose cells, and extracellular matrix were visualized in complex 3-dimensional organization of intact bone marrow tissue revealing unknown features of multicellular architecture. Normal murine bone marrow, after brief fixation formaldehyde, is shown in Figure A. Rat anti-mouse basement-membrane monoclonal antibody (MAb) and fluorescent isothiocyanate (FITC)-labeled donkey anti-rat monoclonal antibody were used to visualize the extracellular matrix and micro-vessels (appearing green). Allophycocyanin (APC)-labeled rat anti-mouse CD45R cells permitted visualization of B lymphocytes (red). 4’,6-diamidino-2-phenylindole(DAPI) stained all nuclei (blue). Nests of lymphocytes appeared encased by extracellular matrix, fed by microvessels running from the bone edge. An example of the architecture of a human hematologic malignancy is shown in figure B, from a marrow biopsy of a patient with multiple myeloma prior to therapy. Mouse anti-human CD20 MAb and FITC-labeled donkey anti-mouse IgG were used to visualize mature B cells (green). APC-conjugated mouse anti-human CD38 MAb identified plasma cells (red). DAPI stained nuclei (blue). The large tumor cells appeared in unevenly distributed cell clumps. In mouse experiments, (not illustrated), marrow cells were easily observed in animals in which GFP was driven by the ubiquitin-C promoter. In humans (also not illustrated), we observed malignant cell populations stained with appropriate lineage-specific antibodies in patients with leukemia and compared CD34 cell numbers in normal with aplastic bone marrow. Confocal laser scanning microscopy, a powerful technique to generate serial sections of whole-mount tissue and their digital reassembly into virtual 3-dimensional structures, has been readily adapted to examination of murine and human bone marrow. The wide variety of MAbs available for specific antigens in combination with this imaging method should aid in conceptualizing microanatomical relationships among hematopoietic cells, stroma, blood vessels, and extracellular matrix in normal and diseased bone marrow. Figure Figure


Blood ◽  
2000 ◽  
Vol 96 (2) ◽  
pp. 671-675 ◽  
Author(s):  
Sun Jin Choi ◽  
Jose C. Cruz ◽  
Fiona Craig ◽  
Hoyeon Chung ◽  
Rowena D. Devlin ◽  
...  

This study was designed to determine if macrophage inhibitory protein-1 (MIP-1), a recently described osteoclast (OCL) stimulatory factor,1 was present in marrow from patients with multiple myeloma (MM) and possibly involved in the bone destructive process. MIP-1, but not interleukin-1β (IL-1β), tumor necrosis factor-β (TNF-β), or interleukin-6 (IL-6), messenger RNA was elevated in freshly isolated bone marrow from 3 of 4 patients with MM compared to normal controls. Furthermore, enzyme-linked immunosorbent assays of freshly isolated bone marrow plasma detected increased concentrations of hMIP-1 (range, 75-7784 pg/mL) in 8 of 13 patients (62%) with active myeloma, in 3 of 18 patients (17%) with stable myeloma (range, 75-190.3), as well as in conditioned media from 4 of 5 lymphoblastoid cell lines (LCLs) derived from patients with MM. Mildly elevated levels of MIP-1 were detected in 3 of 14 patients (21%) with other hematologic diagnoses (range, 80.2-118.3, median value of 96 pg/mL) but not in normal controls (0 of 7). MIP-1 was not detected in the peripheral blood of any patients with MM. In addition, recombinant hMIP-1 induced OCL formation in human bone marrow cultures. Importantly, addition of a neutralizing antibody to MIP-1 to human bone marrow cultures treated with freshly isolated marrow plasma from patients with MM blocked the increased OCL formation induced by these marrow samples but had no effect on control levels of OCL formation. Thus, high levels of MIP-1 are expressed in marrow samples from patients with MM, but not in marrow from patients with other hematologic disorders or controls, and support an important role for MIP-1 as one of the major factors responsible for the increased OCL stimulatory activity in patients with active MM.


Sign in / Sign up

Export Citation Format

Share Document